Chronic kidney disease, Lancet Lond Engl, vol.379, issue.9811, pp.165-80, 2012. ,
,
, Nephrol Ther, vol.7, issue.7, pp.566-81, 2011.
Impact of cadaveric renal transplantation on survival in patients listed for transplantation, J Am Soc Nephrol JASN, vol.16, issue.6, pp.1859-65, 2005. ,
Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol JASN, vol.11, issue.5, pp.917-939, 2000. ,
The economics and ethics of kidney transplantation: perspectives in 2006, Curr Opin Nephrol Hypertens, vol.15, issue.6, pp.593-601, 2006. ,
, HAS. Transplantation rénale. Accès à la liste d'attente nationale, 2017.
Immunomodulation dans la greffe rénale : ce qui a changé en 20 ans. Réanimation, vol.15, pp.253-261, 2006. ,
, Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial, Lancet Lond Engl, vol.2, issue.8357, pp.986-995, 1983.
, Agence de la biomédecine-Le rapport annuel médical et scientifique, 2015.
, Suivi ambulatoire de l'adulte transplanté rénal au-delà de 3 mois après transplantation, HAS, 2017.
, Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.9, issue.3, pp.1-155, 2009.
Immunosuppressive drugs for kidney transplantation, N Engl J Med, vol.351, issue.26, pp.2715-2744, 2004. ,
Today in molecular mechanisms of immunosuppressive drugs actions: roles of pharmacist ,
, Ann Pharm Fr, vol.66, issue.2, pp.102-116, 2008.
Ability of a first-pass pharmacokinetic model to characterize cyclosporine blood concentrations after administrations of Sandimmune or Neoral formulations, Ther Drug Monit, vol.20, issue.2, pp.165-71, 1998. ,
Role of pharmacogenetics of immunosuppressive drugs in organ transplantation, Ther Drug Monit, vol.30, issue.2, pp.143-50, 2008. ,
Population pharmacokinetics of cyclosporine in transplant recipients, AAPS J, vol.15, issue.4, pp.901-913, 2013. ,
In vitro metabolism of cyclosporine A by human kidney CYP3A5, Biochem Pharmacol, vol.68, issue.9, pp.1889-902, 2004. ,
Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients, Br J Clin Pharmacol, vol.64, issue.6, pp.750-757, 2007. ,
Clinical pharmacokinetics of tacrolimus, Clin Pharmacokinet, vol.29, issue.6, pp.404-434, 1995. ,
Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients, Transplantation, vol.76, issue.8, pp.1233-1238, 2003. ,
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation, Clin Pharmacokinet, vol.43, issue.10, pp.623-53, 2004. ,
Sirolimus and everolimus in kidney transplantation, Drug Discov Today, vol.20, issue.10, pp.1243-1252, 2015. ,
A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients, Clin Pharmacokinet, vol.55, issue.11, pp.1447-56, 2016. ,
Clinical pharmacokinetics of sirolimus, Clin Pharmacokinet, vol.40, issue.8, pp.573-85, 2001. ,
Clinical pharmacokinetics of everolimus, Clin Pharmacokinet, vol.43, issue.2, pp.83-95, 2004. ,
Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity, Clin Transplant, vol.14, issue.2, pp.97-109, 2000. ,
Identification of the UDPglucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism, Drug Metab Dispos Biol Fate Chem, vol.33, issue.1, pp.139-185, 2005. ,
Therapeutic drug monitoring of mycophenolic acid, Clin J Am Soc Nephrol CJASN, vol.2, issue.5, pp.1062-72, 2007. ,
,
, Ann Urol, vol.41, issue.6, pp.276-84, 2007.
, Nulojix 250 mg, 2016.
Belatacept and Long-Term Outcomes in Kidney Transplantation, N Engl J Med, vol.374, issue.26, pp.2600-2601, 2016. ,
Belatacept Compared to Tacrolimus for Kidney Transplantation: A Propensity Score Matched Cohort Study, Transplantation, 2016. ,
Cancer in the transplant recipient. Cold Spring Harb Perspect Med, vol.3, 2013. ,
Spectrum of cancer risk among US solid organ transplant recipients, JAMA, vol.306, issue.17, pp.1891-901, 2011. ,
Cancers after renal transplantation, Transplant Rev Orlando Fla, vol.22, issue.2, pp.141-150, 2008. ,
Cancer risk following organ transplantation: a nationwide cohort study in Sweden, Br J Cancer, vol.89, issue.7, pp.1221-1228, 2003. ,
Cancer after kidney transplantation in the United States, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.4, issue.6, pp.905-918, 2004. ,
Cancer immunology, N Engl J Med, vol.358, issue.25, pp.2704-2719, 2008. ,
Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience, Ther Adv Urol, vol.8, issue.5, pp.319-345, 2016. ,
Post-transplantation malignancies: here today, gone tomorrow?, Nat Rev Clin Oncol, vol.12, issue.12, pp.705-722, 2015. ,
,
, Nephrol Ther, vol.12, issue.6, pp.468-87, 2016.
Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies, Transplantation, vol.80, issue.7, pp.883-892, 2005. ,
PIK3CA is implicated as an oncogene in ovarian cancer, Nat Genet, vol.21, issue.1, pp.99-102, 1999. ,
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nat Med, vol.8, issue.2, pp.128-163, 2002. ,
Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and metaanalysis of individual patient data, BMJ, vol.349, p.6679, 2014. ,
Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study, Am J Transplant, vol.9, issue.5, pp.1115-1138, 2009. ,
Cancer and immunosuppression: pro-and antitumoral effects of immunosuppressive drugs ,
, Nephrol Ther, vol.1, issue.1, pp.23-30, 2005.
Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids, Am J Respir Cell Mol Biol, vol.16, issue.4, pp.398-406, 1997. ,
Glucocorticoid effects on angiogenesis are associated with mTOR pathway activity, Biotech Histochem Off Publ Biol Stain Comm, vol.91, issue.4, pp.296-306, 2016. ,
Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells, Br J Dermatol, vol.113, issue.6, pp.723-732, 1985. ,
Cyclosporine induces cancer progression by a cell-autonomous mechanism, Nature, vol.397, issue.6719, pp.530-534, 1999. ,
DOI : 10.1038/17401
Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer, Cancer Res, vol.68, issue.14, pp.5689-98, 2008. ,
Projection de l'incidence et de la mortalité par cancer urologique en France en 2012, Prog En Urol, vol.23, pp.57-65, 2013. ,
,
, Progres En Urol J Assoc Francaise Urol Soc Francaise Urol, vol.27, issue.1, pp.27-51, 2016.
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours, Eur Urol, vol.70, issue.1, pp.93-105, 2016. ,
Immune signature of tumor infiltrating immune cells in renal cancer, Oncoimmunology, vol.4, issue.1, p.985082, 2015. ,
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol, vol.27, issue.5, pp.58-68, 2016. ,
International variations and trends in renal cell carcinoma incidence and mortality, Eur Urol, vol.67, issue.3, pp.519-549, 2015. ,
Prognostic significance of morphologic parameters in renal cell carcinoma, Am J Surg Pathol, vol.6, issue.7, pp.655-63, 1982. ,
Prognostic value of nuclear grade of renal cell carcinoma. Cancer, vol.76, pp.2543-2552, 1995. ,
Renal-cell carcinoma-molecular pathways and therapies, N Engl J Med, vol.356, issue.2, pp.185-192, 2007. ,
DOI : 10.1056/nejme068263
Renal-cell carcinoma, N Engl J Med, vol.353, issue.23, pp.2477-90, 2005. ,
VEGF targets the tumour cell, Nat Rev Cancer, vol.13, issue.12, p.871, 2013. ,
Identification of the von HippelLindau disease tumor suppressor gene, Science, vol.260, issue.5112, pp.1317-1337, 1993. ,
VHL, the story of a tumour suppressor gene, Nat Rev Cancer, vol.15, issue.1, pp.55-64, 2015. ,
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma, N Engl J Med, vol.374, issue.2, pp.135-180, 2016. ,
Regulation of the MET oncogene: molecular mechanisms, Carcinogenesis, vol.37, issue.4, pp.345-55, 2016. ,
Pharmacotherapy for treating metastatic clear cell renal cell carcinoma, Expert Opin Pharmacother, vol.18, issue.2, pp.205-221, 2017. ,
,
, Progres En Urol J Assoc Francaise Urol Soc Francaise Urol, vol.15, issue.6, pp.1021-1030, 2005.
Signal transduction by vascular endothelial growth factor receptors, Biochem J, vol.15, issue.2, pp.169-83, 2011. ,
EGFR and VEGFR2 protein expressions in bone metastases of clear cell renal cancer, Anticancer Res, vol.27, issue.2, pp.889-94, 2007. ,
Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial ?5 integrin, Cancer Res, vol.73, issue.14, pp.4579-90, 2013. ,
Pro-and anti-cancer effects of immunosuppressive agents used in organ transplantation, Transplantation, vol.77, issue.12, pp.1777-82, 2004. ,
VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer, Lung Cancer Amst Neth, vol.46, issue.3, pp.293-301, 2004. ,
Association of VEGF and VEGFR1 polymorphisms with breast cancer risk in North Indians, Tumour Biol J Int Soc Oncodevelopmental Biol Med, vol.36, issue.6, pp.4223-4257, 2015. ,
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy, Oncotarget, vol.6, issue.22, pp.19305-19320, 2015. ,
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors, Mol Cancer Ther, vol.8, issue.9, pp.2496-508, 2009. ,
Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production, Cytokine, vol.12, issue.8, pp.1232-1237, 2000. ,
Polymorphisms in the VEGFA promoter are associated with susceptibility to hepatocellular carcinoma by altering promoter activity, Int J Cancer J Int Cancer, vol.133, issue.5, pp.1085-93, 2013. ,
VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population, Hum Immunol, vol.74, issue.1, pp.98-103, 2013. ,
VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma, J Urol, vol.184, issue.4, pp.1273-1281, 2010. ,
Predictive value of vascular endothelial growth factor polymorphisms on the risk of renal cell carcinomas: a case-control study, Tumour Biol J Int Soc Oncodevelopmental Biol Med, vol.36, issue.11, pp.8645-52, 2015. ,
Association of a singlenucleotide polymorphism in the promoter region of the VEGF gene with the risk of renal cell carcinoma, Genet Test Mol Biomark, vol.15, issue.9, pp.653-660, 2011. ,
Association between SNPs in vascular endothelial growth factor polymorphisms and risk of renal cell carcinoma: a case-control study, Genet Mol Res GMR, vol.14, issue.3, pp.11119-11144, 2015. ,
Predictive value of vascular endothelial growth factor polymorphisms on the risk of renal cell carcinomas, Genet Mol Res GMR, vol.13, issue.3, pp.7634-7676, 2015. ,
Vascular endothelial growth factor gene polymorphisms and the risk of renal cell carcinoma: Evidence from eight case-control studies, Oncotarget, vol.8, issue.5, pp.8447-58, 2017. ,
A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk, Int J Cancer, vol.106, issue.4, pp.468-71, 2003. ,
A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels, J Vasc Res, vol.37, issue.6, pp.443-451, 2000. ,
Contribution of VEGF polymorphisms to variation in VEGF serum levels in a healthy population, Eur Cytokine Netw, vol.22, issue.3, pp.154-162, 2011. ,
VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma, Anticancer Res, vol.33, issue.11, pp.5017-5039, 2013. ,
Single Nucleotide Polymorphisms in the 3′ Untranslated Region of Vascular Endothelial Growth Factor Gene in Japanese Population with or without Renal Cell Carcinoma, Tohoku J Exp Med, vol.198, issue.3, pp.181-90, 2002. ,
Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas, Eur Urol, vol.52, issue.4, pp.1147-55, 2007. ,
Predictive role of vascular endothelial growth factor polymorphisms in the survival of renal cell carcinoma patients, Genet Mol Res GMR, vol.13, issue.3, pp.5011-5018, 2014. ,
Association of vascular endothelial growth factor polymorphisms with clinical outcome of renal cell carcinoma patients, Tumour Biol J Int Soc Oncodevelopmental Biol Med, vol.35, issue.10, pp.9839-9884, 2014. ,
Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients, Oncol Lett, vol.9, issue.2, pp.651-657, 2015. ,
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib, Br J Cancer, vol.108, issue.5, pp.1126-1158, 2013. ,
Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinibtreated metastatic renal cell carcinoma patients, J Cancer Res Clin Oncol, vol.142, issue.6, pp.1171-82, 2016. ,
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study, Lancet Oncol, vol.12, issue.12, pp.1143-50, 2011. ,
Influence of VEGFR single nucleotide polymorphisms on the efficacy of sunitinib therapy against renal cell carcinoma, Oncol Lett, vol.13, issue.1, pp.201-206, 2017. ,
The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer, Gynecol Oncol, vol.117, issue.1, pp.109-125, 2010. ,
Variants in angiogenesis-related genes and the risk of clear cell renal cell carcinoma, Mutagenesis, vol.29, issue.6, pp.419-444, 2014. ,
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma, Cancer Chemother Pharmacol, vol.74, issue.4, pp.739-50, 2014. ,
High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Mol Cell Endocrinol, vol.425, pp.61-69, 2016. ,
Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma, PloS One, vol.4, issue.6, p.6037, 2009. ,
Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian "tumor of breast tissue: incidence, genetics, and environmental risk factors" study, Breast Cancer Res Treat, vol.109, issue.2, pp.297-304, 2008. ,
Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer, Eur J Cancer Oxf Engl, vol.44, issue.11, pp.1572-1578, 1990. ,
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma. Sci Rep, vol.6, 2016. ,
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib, Clin Cancer Res Off J Am Assoc Cancer Res, vol.17, issue.3, pp.620-629, 2011. ,
De novo kidney graft tumors: results from a multicentric retrospective national study, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.12, issue.12, pp.3308-3323, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00942810
Renal Cell Cancer in a European Regional Renal Transplant Population: Is There a Role for Immediate Native Renal Radiological Surveillance Before and After Transplantation?, Transplant Proc, vol.47, issue.6, pp.1840-1844, 2015. ,
Renal cell carcinoma in kidney transplant recipients and dialysis patients, Korean J Urol, vol.53, issue.4, pp.229-262, 2012. ,
Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities? BJU Int, vol.110, pp.570-573, 2012. ,
Differences in Clinical and Pathological Features of Renal Cell Carcinoma Between Japanese Patients After Kidney Transplantation and Those on Hemodialysis, Ther Apher Dial Off Peer-Rev J, 2017. ,
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population, Eur Urol, vol.60, issue.2, pp.366-73, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00577215
Cancer risk in patients on dialysis and after renal transplantation, Lancet Lond Engl, vol.355, issue.9218, pp.1886-1893, 2000. ,
Cancer incidence before and after kidney transplantation, JAMA, vol.296, issue.23, pp.2823-2854, 2006. ,
Association of CKD and cancer risk in older people, J Am Soc Nephrol JASN, vol.20, issue.6, pp.1341-50, 2009. ,
Conversion of longterm kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study, Transplantation, vol.92, issue.4, pp.410-418, 2011. ,
, Reference SNP (refSNP) Cluster Report: rs699947 ** other ** [Internet, p.2017
Epidemiology and risk factors for kidney cancer, Nat Rev Urol, vol.7, issue.5, pp.245-57, 2010. ,
, Guide affection longue durée-Cancer du rein de l'adulte-HAS, p.2017, 2010.
Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers, Oncotarget, 2017. ,
The VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women, Cancer Lett, vol.262, issue.1, pp.71-77, 2008. ,
Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro, Nature, vol.332, issue.6164, pp.557-61, 1988. ,
Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity, Genes Dev, vol.4, issue.10, pp.1741-52, 1990. ,